drugset / Trial / NCT07714369
Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache
Phase 2
Not yet recruiting
40 enrolled
The University of Texas Health Science Center, Houston
Pfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess headache response rate for minimal pain at 30 minutes following zavegepant administration and to assess additional effectiveness and treatment failure endpoints at various timepoints after zavegepant administration
Timeline
- Start
- 2026-10-01
- Primary completion
- 2028-04-01
- Completion
- 2028-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zavegepant | Small molecule | 10 mg | Intranasal |